Exploration of the Relationship of Reduction in HbA1c and Body Weight by Dapagliflozin in Patients With T2DM: Pooled Analysis of 5 Clinical Trials

被引：0
|
作者：
Hardy, Elise
Salsali, Afshin
Wessman, Catrin
Wei, Li
Mansfield, Traci
Parikh, Shamik
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
987-P
引用
收藏
页码：A252 / A252
页数：1
相关论文
共 50 条
  • [41] Long-Term Clinical Outcomes Associated With LDL-C and HbA1c Goal Achievement in Patients With Type 2 Diabetes Mellitus (T2DM)
    Shi, Lizheng
    Ye, Xin
    Lu, Mei
    Wu, Eric Q.
    Sharma, Hari
    Thomason, Darren
    Fonseca, Vivian
    DIABETES, 2013, 62 : A392 - A392
  • [42] Responder Analysis of Subjects Achieving HbA1c ≥1% and Weight Loss ≥5% across SUSTAIN 1-5 Clinical Trials
    Rodbard, Helena W.
    Bellary, Srikanth
    Hramiak, Irene
    Seino, Yutaka
    Silver, Robert J.
    Bergan, Eirik Q.
    Birch, Sune
    Aroda, Vanita R.
    DIABETES, 2017, 66 : A299 - A299
  • [43] Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials
    Bellary, S.
    Rodbard, H.
    Hramiak, I.
    Seino, Y.
    Silver, R.
    Bergan, E. Q.
    Birch, S.
    Aroda, V.
    DIABETIC MEDICINE, 2018, 35 : 34 - 34
  • [44] Responder analysis of subjects achieving HbA1c≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials
    Rodbard, H. W.
    Bellary, S.
    Hramiak, I.
    Seino, Y.
    Silver, R.
    Bergan, E. Q.
    Birch, S.
    Aroda, V. R.
    DIABETOLOGIA, 2017, 60 : S379 - S379
  • [45] Dapagliflozin helps reduce HbA1c and body weight in patients with type 2 diabetes as part of triple combination therapy: a subanalysis of four clinical studies
    Jabbour, S.
    Hardy, E.
    de Bruin, T. W.
    Gause-Nilsson, I.
    Rohwedder, K.
    Martin, P.
    Parikh, S.
    DIABETOLOGIA, 2013, 56 : S375 - S375
  • [46] Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
    Abdul-Ghani, Muhammad
    Migahid, Osama
    Megahed, Ayman
    DeFronzo, Ralph A.
    Zirie, Mahmoud
    Jayyousi, Amin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (07): : 2162 - 2170
  • [47] Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%
    Merker, Ludwig
    Lund, Soren S.
    Hantel, Stefan
    Salsali, Afshin
    Kim, Gabriel
    Broedl, Uli C.
    Woerle, Hans J.
    Hach, Thomas
    DIABETES, 2014, 63 : A280 - A281
  • [48] Efficacy and Safety of Vildagliptin in Triple Combination With Metformin Plus Sulfonylurea in Subgroup of Patients With T2DM and Baseline HbA1c
    Lukashevich, Valentina
    Araga, Mako
    Kothny, Wolfgang
    DIABETES, 2013, 62 : A294 - A294
  • [49] Baseline HbA1c Level Correlates with Vildagliptin's Efficacy for T2DM Treatment: A Subgroup Analysis of VISION Study
    Ji, Li Nong
    Zhou, Ling Li
    Pan, Chang Yu
    Lu, Ju Ming
    Wang, Le
    Wang, Bin Hui
    He, James
    DIABETES, 2017, 66 : A628 - A628
  • [50] Achievement of HbA1c Goal and Body Weight and Systolic Blood Pressure Reduction When Treated with Dapagliflozin in Patients with Type 2 Diabetes Stratified by Disease Duration
    Yeh, Helen
    Katz, Arie
    Moran, Jason
    DIABETES, 2015, 64 : A313 - A313
12345